^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    16h
    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD (clinicaltrials.gov)
    P3, N=376, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    20h
    A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Guangdong Hengrui Pharmaceutical Co., Ltd
    New P2 trial
    22h
    An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Massachusetts General Hospital
    New P2 trial • Adverse events • Checkpoint inhibition
    1d
    Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov)
    P2, N=50, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Recruiting
    Enrollment open
    2d
    Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=50, Recruiting, Horus University
    New P2 trial
    |
    roflumilast
    3d
    Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    8d
    Roflumilast prevented tissue damage caused by lipopolysaccharide-induced sepsis via anti-inflammatory action. (PubMed, PLoS One)
    While 1.5 mg/kg Roflumilast showed no protective effects, 3 mg/kg markedly reduced inflammatory and injury markers, improved tissue architecture, and decreased KIM-1 expression. These findings suggest that a higher dose of Roflumilast effectively mitigates LPS-induced systemic inflammation and organ injury, supporting its potential as a therapeutic option for sepsis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • KIM1 (Kidney injury molecule 1) • IL1B (Interleukin 1, beta)
    |
    roflumilast
    8d
    TAM-AMIN-UAS: Tamsulosin and Intraureteral Aminophylline for Ureteral Access During RIRS (clinicaltrials.gov)
    P2, N=322, Recruiting, Beni-Suef University
    New P2 trial
    9d
    Intravesical Aminophylline for Urgent Ureteral Stenting in Acute Calculous Anuria (clinicaltrials.gov)
    P2, N=72, Recruiting, Beni-Suef University
    New P2 trial
    10d
    Intravesical Aminophylline to Facilitate Ureteroscopic Access in Children With Distal Ureteral Stones. (clinicaltrials.gov)
    P2, N=60, Recruiting, Beni-Suef University
    New P2 trial
    13d
    Unveiling Remyelinating Properties of Roflumilast in CPZ-Induced Neuronal Demyelination in Mice. (PubMed, Drug Dev Res)
    Remyelination was confirmed through Luxol fast blue staining, accompanied by reduced apoptotic marker, caspase-3, in oligodendrocytes. Collectively, these findings suggest that ROFL exerts neuroprotective effects and highlight the therapeutic potential of PDE-4 inhibition as a strategy for MS treatment.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • CASP3 (Caspase 3)
    |
    roflumilast
    20d
    Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis (clinicaltrials.gov)
    P1, N=22, Completed, Arcutis Biotherapeutics, Inc. | Recruiting --> Completed | N=16 --> 22 | Trial completion date: Feb 2027 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date